P1108 (DAIDS ID 11884): A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease

Study Trainings:

2017 Annual Meeting MDR-TB Training - May 2017

P1108 Training - February 2017
Cape Town, South Africa

Related Publications:

  • Adverse Effects of Oral Second Line Antituberculosis Drugs in Children
  • Safety and Tolerability of the Second Line Injectable Antituberculosis Drugs in Children

    Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.